Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 747 results
Found 747 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

C

Angelidou K, Hunt PW, Landay AL, et al. "Changes in Inflammation but Not in T-Cell Activation Precede Non-AIDS-Defining Events in a Case-Control Study of Patients on Long-term Antiretroviral Therapy." J. Infect. Dis.. 2018;218(2):239-248.
Dirajlal-Fargo S, Moser C, Brown TT, et al. "Changes in Insulin Resistance After Initiation of Raltegravir or Protease Inhibitors With Tenofovir-Emtricitabine: AIDS Clinical Trials Group A5260s." Open Forum Infect Dis. 2016;3(3):ofw174.
Kelesidis T, Moser C, Stein JH, et al. "Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s." J. Infect. Dis.. 2016.
Krishnan S, Schouten JT, Atkinson B, et al. "Changes in metabolic syndrome status after initiation of antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2015;68(1):73-80.
Kelesidis T, Tran TTien T, Brown TT, et al. "Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s." Antivir. Ther. (Lond.). 2016.
Wyatt CM, Kitch D, Gupta SK, et al. "Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine." J. Acquir. Immune Defic. Syndr.. 2014;67(1):36-44.
Bosch RJ, Wang R, Vaida F, Lederman MM, Albrecht MA. "Changes in the slope of the CD4 cell count increase after initiation of potent antiretroviral treatment." J. Acquir. Immune Defic. Syndr.. 2006;43(4):433-5.
Li JZ, Brumme CJ, Lederman MM, et al. "Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial." PLoS ONE. 2012;7(3):e34134.
Robbins GK, Cohn SE, Harrison LJ, et al. "Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251." HIV Clin Trials. 2016;17(4):165-72.
Smith DM, Drumright LN, Frost SDW, et al. "Characteristics of recently HIV-infected men who use the Internet to find male sex partners and sexual practices with those partners." J. Acquir. Immune Defic. Syndr.. 2006;43(5):582-7.
Thio CL, Smeaton L, Saulynas M, et al. "Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort." AIDS. 2013;27(2):191-201.
Mugavero MJ, Pence BW, Whetten K, et al. "Childhood abuse and initial presentation for HIV care: an opportunity for early intervention." AIDS Care. 2007;19(9):1083-7.
De Luca A, Ammassari A, Pezzotti P, et al. "Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis." AIDS. 2008;22(14):1759-67.
Riddler SA, Haubrich R, A DiRienzo G, et al. "Class-sparing regimens for initial treatment of HIV-1 infection." N. Engl. J. Med.. 2008;358(20):2095-106.
Vardhanabhuti S, Acosta EP, Ribaudo HJ, et al. "Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission." J. Infect. Dis.. 2013;208(4):662-71.
Grant PM, Komarow L, Sanchez A, et al. "Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164." HIV Clin Trials. 2014;15(4):133-9.
Wohl DA, Kendall MA, Feinberg J, et al. "The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit." PLoS ONE. 2013;8(11):e78676.
Schifitto G, Deng L, Yeh T-min, et al. "Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals." J. Neurovirol.. 2011;17(1):17-25.
Haas DW, Mootsikapun P, Ruxrungtham K, Podzamczer D. "Clinical perspectives on human genetic screening to prevent nevirapine toxicity." Per Med. 2012;9(7):773-782.
Gay CL, Bosch RJ, Ritz J, et al. "Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy." J. Infect. Dis.. 2017;215(11):1725-1733.
Smith D, Moini N, Pesano R, et al. "Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection." Clin. Infect. Dis.. 2007;44(3):456-8.
Wagner GJ, Goggin K, Remien RH, et al. "A closer look at depression and its relationship to HIV antiretroviral adherence." Ann Behav Med. 2011;42(3):352-60.
Gange SJ, Kitahata MM, Saag MS, et al. "Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)." Int J Epidemiol. 2007;36(2):294-301.
Paredes R, Tzou PL, van Zyl G, et al. "Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation." PLoS ONE. 2017;12(7):e0181357.
Vogler MA, Smeaton LM, Wright RL, et al. "Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227." J. Acquir. Immune Defic. Syndr.. 2014;65(5):542-50.
Luetkemeyer AF, Rosenkranz SL, Lu D, et al. "Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study." Clin. Infect. Dis.. 2015;60(12):1860-3.
Healy B, De Gruttola V, Pagano M. "Combining cross-sectional and prospective data methods to improve transition parameter estimation for characterizing the accumulation of HIV-1 drug resistance mutations." Biometrics. 2007;63(3):742-50.
Podany AT, Scarsi KK, Fletcher CV. "Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors." Clin Pharmacokinet. 2017;56(1):25-40.
Mugavero MJ, May M, Ribaudo HJ, et al. "Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study." J. Acquir. Immune Defic. Syndr.. 2011;58(3):253-60.
Bartlett JA, Chen S-S, Quinn JB. "Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview." HIV Clin Trials. 2007;8(4):221-6.

Pages